Stephen A. Sherwin, serving as a director at Neurocrine Biosciences Inc. (NASDAQ: NBIX), executed a significant transaction involving the sale of common stock on June 5, 2026. According to a recent Securities and Exchange Commission filing, the sale encompassed 25,000 shares, resulting in proceeds totaling approximately $4.13 million. The shares were divested at prices ranging between $163.11 and $167.70 per share during the transaction.
The execution of this sale was facilitated under a Rule 10b5-1 trading plan. This automated trading framework was initially adopted by Sherwin on March 6, 2026, establishing the parameters for the subsequent disposition of shares. The timing of the sale occurs as Neurocrine Biosciences stock trades in close proximity to its 52-week high of $169.57. Over the preceding 12 months, the share price has appreciated by 31%.
Market analysis from InvestingPro suggests that the company may be trading below its intrinsic value, citing a Fair Value estimate of $207.60. This valuation gap implies potential upside for investors. The platform highlights additional metrics, including positive earnings revisions from 11 analysts, which contribute to the broader assessment of the stock's fundamentals.
In a concurrent transaction on the same date, June 5, 2026, Sherwin acquired 25,000 shares of Neurocrine Biosciences common stock. These shares were obtained through the exercise of non-qualified stock options. The total value of this acquisition was approximately $1.60 million, with exercise prices ranging from $53.64 to $79.79 per share. Following these combined transactions, Sherwin's direct ownership of Neurocrine Biosciences common stock stands at 15,860 shares.
Recent developments in the pharmaceutical sector highlight ongoing clinical and commercial activities for Neurocrine Biosciences. The company presented clinician-reported data at the American Academy of Developmental Medicine and Dentistry’s annual conference. This data indicated improvements in tardive dyskinesia severity among patients treated with INGREZZA, specifically noting impacts on individuals with intellectual and developmental disabilities. Furthermore, Neurocrine announced plans to present two-year clinical data on CRENESSITY at the Endocrine Society’s annual meeting in 2026. This presentation will focus on treatment outcomes for classic congenital adrenal hyperplasia.
In the investment community, Goldman Sachs resumed coverage of Neurocrine Biosciences with a buy rating, setting a price target of $213. The firm cited the completion of the Soleno Therapeutics acquisition as a catalyst, noting the introduction of Vykat XR for Prader-Willi syndrome as a factor enhancing revenue growth potential. Simultaneously, Bernstein initiated coverage with an outperform rating and a price target of $221. Bernstein emphasized the drug potential of Crenessity and Ingrezza as key drivers for the company's market position.
The integration of Soleno Therapeutics and the associated product pipeline expansions reflect ongoing efforts to strengthen Neurocrine's commercial portfolio. The alignment of analyst price targets with the stock's recent performance underscores the market's focus on the company's therapeutic advancements and strategic acquisitions.